Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1979 1
1980 4
1981 8
1982 9
1983 6
1984 9
1985 18
1986 13
1987 22
1988 23
1989 38
1990 42
1991 18
1992 32
1993 43
1994 46
1995 56
1996 62
1997 65
1998 68
1999 90
2000 100
2001 122
2002 128
2003 195
2004 207
2005 258
2006 295
2007 332
2008 433
2009 472
2010 499
2011 621
2012 683
2013 767
2014 902
2015 1038
2016 1071
2017 1183
2018 1280
2019 1490
2020 1717
2021 2025
2022 2478
2023 2361
2024 2748
2025 2366
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,655 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: jin y. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.
Nong K, Jeppesen BT, Shi Q, Agoritsas T, Guyatt GH, White H, Gao Y, Agarwal A, Macdonald H, Zou X, Millard T, Schnell O, Marx N, Brosius FC 3rd, McDonald S, Quigley M, Tian X, Fan Q, White B, Mao Y, Pan X, Liu C, Zhai C, Yuan C, Li Q, An J, Gan Y, Wang Y, Jin Y, Sun F, Zhu Z, Rydén L, Standl E, Turner T, Vandvik PO, Li S. Nong K, et al. Among authors: jin y. BMJ. 2025 Aug 14;390:e083039. doi: 10.1136/bmj-2024-083039. BMJ. 2025. PMID: 40813122
Integrative proteogenomic characterization of Wilms tumor.
Cheng C, Zhang L, Chang X, Chen K, He T, Shi J, Lv F, Pan L, Wu Y, Cheng Q, Ren D, Guo Y, Zhang W, Wang H, Shi T, Li J, Ni X, Wu Y, Jin Y, Wu Z. Cheng C, et al. Among authors: jin y. Nat Commun. 2025 Aug 19;16(1):7715. doi: 10.1038/s41467-025-62234-7. Nat Commun. 2025. PMID: 40830093 Free PMC article.
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers.
Theardy MS, Takeda M, Sorokin A, Chen S, Yang Z, Wang X, Kanikarla P, Coker O, Nguyen P, Wei Y, Yao J, Yan L, Jin Y, Cai Y, Paku M, Chen Z, Li KZ, Citron F, Tomihara H, Gao S, Deem AK, Zhao J, Wang H, Hanash S, DePinho RA, Maitra A, Draetta GF, Ying H, Kopetz S, Yao W. Theardy MS, et al. Among authors: jin y. Cell Rep Med. 2025 Aug 19;6(8):102253. doi: 10.1016/j.xcrm.2025.102253. Epub 2025 Jul 25. Cell Rep Med. 2025. PMID: 40713971 Free PMC article.
Record-breaking 2023 marine heatwaves.
Dong T, Zeng Z, Pan M, Wang D, Chen Y, Liang L, Yang S, Jin Y, Luo S, Liang S, Huang X, Zhao D, Ziegler AD, Chen D, Li LZX, Zhou T, Zhang D. Dong T, et al. Among authors: jin y. Science. 2025 Jul 24;389(6758):369-374. doi: 10.1126/science.adr0910. Epub 2025 Jul 24. Science. 2025. PMID: 40705884
23,655 results
You have reached the last available page of results. Please see the User Guide for more information.